SYDNEY – Kazia Therapeutics Limited (NASDAQ: KZIA), a small-cap biotechnology company (market cap of US$13.5 million) focused on oncology medicines, filing with the US Food and Drug Administration (FDA) ) on the Entwicklungsweg before the signal Hirnkrebsmedikament Paxalisib abgeschlossen. Laut InvestPro-Analyze de Aktie der Zeit under my fair trade, where analysts have proven the market volatility (Beta 1.99) a net profit in those years. During the dialogue we followed in July during the study, patients were recently diagnosed with Paxalisib in patients with a new diagnosis of a Glioblastoma (NDU GBM) in the course of standard treatment.
The FDA has done this, but the data (OS) from the GBM-AGILE trial that has not had a single continuous study is a traditional way to promote deployment. The research concerns the development of the design of a separate phase 3 study, which is for a standard test order. Because as much as possible is about the patient population, the primary endpoint and comparison arm for the best study.
Dr. John Friend, CEO of Kazia, thanks the collected feedback from the FDA and access to the continued outcome of the GBM-AGILE study, a 3.8-month outcome study, a next step for Paxalisib in a further investigation is warranted.
Paxalisib is also used for other pediatric indications and health conditions. The drug containing orphan drug and rare pediatric disease designations for the best pädiatric Krebsarten was Kazia possible for pädiatric Prüfgutscheine at qualified product. Vielversprechende data on a short-term growth in the ability of paxalisib with the treatment of bruuskrebs with specific mutations.
Kazia has become active by writing NDU-Glioblastomas and the factory, their strategy for maximizing shareholder value until the end of January 2025 to ski. Während der financial health score of the Unternehmens laut InvestPro Because SCHWACH made a forecast in 2025 from analysts that had an increase of 7.91% for the fiscal year 2025, it had appeared in the background. This announcement is based on a press conference by Kazia Therapeutics Limited. Entdecken Sie 8 weitere exclusive Einblicke and Echte-Metriken with the following analysis tools from InvestPro.
In others, Kazia Therapeutics has deployed a fortschritte in the Krebsforschung force. If you have another type of C-Treffen with the FDA, there is a way to distribute your health medication Paxalisib. The GBM AGILE Phase II/III trial for the treatment of Glioblastoma has made a meaningful study of patients in patients treated with paxalisib. Due to a report on one of the most common phase I studies of Paxalisib in combination with Strahlentherapie, there is a very convincing analysis of the results.
If you do a study on the fortschritte in the blessing EVT801 Phase-1-Study for Krebsbehandlung, with positive experiences, there is a stable Erkrankung or a significant development of the patient. Because the portfolio has now been further expanded, it is an exclusive Lizenz for Krebstherapie for QIMR Berghofer Medical Research Institute available.
HC Wainwright has come up with a Kaufrating for Kazia Therapeutics with a concrete of the potential drug candidates of tertiary medicine. Kazia is more interested in his involvement in the reconstruction of the credit agreement during the teilnahme, a bevorstehenden-medizinische konferenzen and the presentation of an ergebnisse from his past study. These entrepreneurial representatives represent the young Fortschritte in the laufende Bemühungen des Unternehmens, within the framework of the Krebsbehandling for innovation.
This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.